Showing 7681-7690 of 8879 results for "".
- CeraVe Expands into Haircare with Launch of Anti-Dandruff and Gentle Hydrating Productshttps://practicaldermatology.com/news/cerave-expands-haircare-launch-anti-dandruff-and-gentle-hydrating-products/2468510/CeraVe has announced the launch of Anti-Dandruff and Gentle Hydrating Products, leadin
- 'Me & My Inner Circle' Launches on World Psoriasis Dayhttps://practicaldermatology.com/news/me-my-inner-circle-launches-world-psoriasis-day/2468497/October 29 is World Psoriasis Day, and Almirall recognized the occasion by launching an awareness campaign called “Me & My Inner Circle,” with the support of the International Federation of Psoriasis Associations (IFPA), the company announced. The campaign features Alma, representing a
- Positive Results for Guselkumab for Moderate PsO Patientshttps://practicaldermatology.com/news/positive-results-guselkumab-moderate-pso-patients/2468490/Guselkumab treatment resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, according to data presented at the 44th Annual Fall Clinical Dermatology Conferenc
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- Dupilumab Improves Chronic Spontaneous Urticaria Symptomshttps://practicaldermatology.com/news/dupixent-improves-chronic-spontaneous-urticaria-symptoms/2468471/Dupixent® (dupilumab) significantly reduced itch and hive activity in patients with chronic spontaneous urticaria, according to phase 3 trial data presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts. In a pre
- Verrica To Share Phase 2 Results for VP-315 in BCC Treatment at Fall Clinicalhttps://practicaldermatology.com/news/verrica-share-phase-2-results-vp-315-bcc-treatment-fall-clinical/2468470/Verrica Pharmaceuticals announced today that two abstracts featuring positive topline results from their phase 2 study of VP-315 for the treatment of basal cell carcinoma (BCC) will be presented at the 2024 Fall Clinical Dermatology Conference. The presentations will focus on safety, tole
- Systematic Review Explores Thiamidol’s Impact on Hyperpigmentationhttps://practicaldermatology.com/news/systematic-review-explores-thiamidols-impact-on-skin-discoloration/2468460/Data from a recent systematic review of 14 clinical studies shows topical isobutylamido thiazolyl resorcinol (ITR) provides statistically significant improvement in various types of hyperpigmentation, including melasma, post-inflammatory hyperpigmentation (PIH), and UV-induced hyperpigmentation.<
- LEO Pharma Announced CHE Awareness Campaignhttps://practicaldermatology.com/news/leo-pharma-announced-che-awareness-campaign/2468442/LEO Pharma Inc. has launched Talk to the Hand, a disease awareness campaign for healthcare providers that highlights the risk factors, symptoms, and physical and emotional impact of chronic hand eczema (CHE)—a debilitating skin condition for which there are currently no FDA approved treatments. <
- JOYA Launches Skin Cancer Prevention, Anti-Aging Employee Benefit Platformhttps://practicaldermatology.com/news/joya-launches-skin-cancer-prevention-anti-aging-employee-benefit-platform/2468435/JOYA, the first employee skin health and wellness benefit platform, announced its emergence from stealth mode with $5 million in seed funding from LUX Capital, Mosaic General Partnership, Arsama Trust, and Joyance Partners. The funding will support team expansion, product development, mar
- FDA Clears Accure Laser System for Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-accure-laser-system-acne-vulgaris/2468432/The US Food and Drug Administration (FDA) cleared the Accure Laser System for the long-term treatment of patients with mild-to-severe inflammatory acne vulgaris, according to a press release from Accure Acne, Inc. "This achievement cannot be overstated," Acclure Acne co-founder, chairman o